Want to see AAPG full AI Analyst Report?
Top Page
Ascentage Pharma Group International Unsponsored ADR
(NASDAQ:AAPG)
Select Model
Select Model
Rating:41Neutral
Price Target:
$18.00
▼(-1.59% Downside)
Action:Upgraded
Date:08/06/26
The score is held down primarily by heavy and worsening losses with significant cash burn in 2025, alongside a clear downtrend and weak momentum signals. Revenue growth and strong gross margins provide some support, but valuation is constrained by negative earnings and there is no dividend yield data to offset risk.
Positive Factors
High Gross Margins & Revenue Growth
Sustained strong gross margins and multi-year revenue expansion indicate efficient product economics and growing commercial traction. High gross margins provide durable leverage to scale operating investments as trials and launches progress, supporting long-term margin recovery once R&D and SG&A normalize.
Negative Factors
Severe Cash Burn
Very large and accelerating cash outflows indicate ongoing financing dependency and constrain strategic optionality. Persistent negative operating and free cash flow imply the company will need external capital within months, increasing dilution risk and potentially delaying or reprioritizing clinical programs.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins & Revenue Growth
Sustained strong gross margins and multi-year revenue expansion indicate efficient product economics and growing commercial traction. High gross margins provide durable leverage to scale operating investments as trials and launches progress, supporting long-term margin recovery once R&D and SG&A normalize.
Read all positive factors
Ascentage Pharma Group International Unsponsored ADR (AAPG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.66B
Dividend YieldN/A
Average Volume (3M)8.43K
Price to Earnings (P/E)―
Beta (1Y)0.87
Revenue Growth-41.19%
EPS Growth-159.09%
CountryUS
Employees767
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-13.84
Shares Outstanding93,402,810
10 Day Avg. Volume7,086
30 Day Avg. Volume8,425
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)12.33
Price to Sales (P/S)29.25
P/FCF Ratio-13.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$46.00Price Target Upside151.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.83
Revenue Forecast (FY)$119.18M
Ascentage Pharma Group International Unsponsored ADR Business Overview & Revenue Model
Company Description
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, in...
How the Company Makes Money
null...
Ascentage Pharma Group International Unsponsored ADR Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 558.48M | 980.65M | 221.98M | 209.71M | 27.91M |
| Gross Profit | 426.75M | 951.57M | 191.44M | 187.71M | 24.58M |
| EBITDA | -1.10B | -237.63M | -743.61M | -786.97M | -798.34M |
| Net Income | -1.21B | -405.43M | -925.64M | -882.92M | -782.42M |
Balance Sheet | |||||
| Total Assets | 3.97B | 2.62B | 2.50B | 2.83B | 2.94B |
| Cash, Cash Equivalents and Short-Term Investments | 2.47B | 1.24B | 1.07B | 1.48B | 1.71B |
| Total Debt | 1.98B | 1.67B | 1.80B | 1.79B | 1.08B |
| Total Liabilities | 2.63B | 2.34B | 2.43B | 2.42B | 1.71B |
| Stockholders Equity | 1.33B | 264.19M | 60.42M | 408.66M | 1.23B |
Cash Flow | |||||
| Free Cash Flow | -1.20B | -135.65M | -782.92M | -890.88M | -1.04B |
| Operating Cash Flow | -1.17B | -111.36M | -726.08M | -653.91M | -604.68M |
| Investing Cash Flow | -1.00B | -362.04M | 21.92M | -384.61M | -466.52M |
| Financing Cash Flow | 2.54B | 314.77M | 368.75M | 619.27M | 1.78B |
Ascentage Pharma Group International Unsponsored ADR Technical Analysis
Negative
18.29
Price Trends
37.24
Negative
38.97
Negative
Market Momentum
-1.44
Positive
34.89
Neutral
11.49
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AAPG, the sentiment is Negative. The current price of 18.29 is below the 20-day moving average (MA) of 34.27, below the 50-day MA of 37.24, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -1.44 indicates Positive momentum. The RSI at 34.89 is Neutral, neither overbought nor oversold. The STOCH value of 11.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AAPG.
Ascentage Pharma Group International Unsponsored ADR Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $1.72B | -10.65 | -28.66% | ― | -28.56% | 10.25% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | $1.00B | -3.35 | -207.18% | ― | -7.27% | -48.89% | |
52 Neutral | $1.81B | -12.53 | -0.74% | ― | -69.78% | -106.07% | |
51 Neutral | $1.39B | -9.91 | -35.35% | ― | ― | 28.64% | |
48 Neutral | $1.80B | -194.40 | -2.35% | ― | 20.19% | ― | |
41 Neutral | $1.66B | -8.86 | -123.61% | ― | -41.19% | -159.09% |
* General Sector Average
AAPG
Ascentage Pharma Group International Unsponsored ADR
18.20
-28.20
-60.78%
XNCR
Xencor
25.41
17.82
234.78%
KURA
Kura Oncology
12.33
5.14
71.49%
ZYME
Zymeworks
26.07
11.97
84.89%
ORIC
Oric Pharmaceuticals
13.92
4.32
45.00%
IMCR
Immunocore Holdings
36.02
3.68
11.38%
Ascentage Pharma Group International Unsponsored ADR Corporate Events
Ascentage Pharma CEO Dajun Yang Ranked Among Top Small-Molecule Leaders in 2026 Power List
Jul 27, 2026
On July 26, 2026, Ascentage Pharma announced that its co-founder, Chairman and CEO Dr. Dajun Yang was ranked No. 3 in the Small Molecules category of The Medicine Maker Power List 2026, an annual global ranking of 60 leaders across drug discovery,...
Ascentage Pharma Sets Up US$200 Million Nasdaq ATM Offering Following SEC Shelf Filing
Jul 20, 2026
On July 20, 2026, Ascentage Pharma Group International announced that it had filed an automatic shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission as a well-known seasoned issuer, enabling future offerings of...
Ascentage Pharma Corrects AGM Date Underpinning Equity Incentive Mandate
Jul 14, 2026
Ascentage Pharma Group International, a Hong Kong–listed biopharmaceutical company incorporated in the Cayman Islands and based in Suzhou, China, develops innovative cancer and related therapies while operating under a board structure that i...
Ascentage Pharma Showcases First Pediatric Alrizomadlin Data at ASCO 2026
Jun 1, 2026
Ascentage Pharma reported on May 31, 2026 that it presented its first dataset for alrizomadlin (APG-115), an orally administered, highly selective MDM2-p53 inhibitor, in pediatric solid tumors at the 62nd American Society of Clinical Oncology Annu...
Ascentage Pharma to Present 17 Hematology Clinical Updates at June 2026 EHA Congress
May 13, 2026
On May 12, 2026, Ascentage Pharma Group International, a global biopharmaceutical company specializing in innovative oncology therapies, announced that 17 clinical advances from its core assets will be showcased at the 31st European Hematology Ass...
Ascentage Pharma to Highlight Oncology Portfolio at May–June 2026 Investor Conferences
May 12, 2026
Ascentage Pharma Group International is a global, commercial-stage biopharmaceutical company specializing in innovative oncology therapies, including apoptotic pathway inhibitors, next-generation kinase inhibitors and protein degraders. Its lead p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.